Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. more
Time Frame | PROK | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.88% | -2.12% | -3% |
1-Month Return | -8.48% | -3.42% | -0.73% |
3-Month Return | -38.62% | -11.13% | 2.87% |
6-Month Return | -41.02% | -5.74% | 7.17% |
1-Year Return | -15.64% | 3.97% | 25.31% |
3-Year Return | -84.7% | 1.05% | 28.38% |
5-Year Return | -85.06% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | 1.98M | 3.04M | 3.17M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":62.61,"profit":true},{"date":"2022-12-31","value":95.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | - | (1.98M) | (3.04M) | (3.17M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-198400000,"profit":false},{"date":"2022-12-31","value":-303600000,"profit":false},{"date":"2023-12-31","value":-316900000,"profit":false}] |
Gross Margin | - | - | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 79.38M | 27.02M | 55.11M | 153.01M | 151.52M | [{"date":"2019-12-31","value":51.88,"profit":true},{"date":"2020-12-31","value":17.66,"profit":true},{"date":"2021-12-31","value":36.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.03,"profit":true}] |
Operating Income | (19.16M) | (27.02M) | (55.11M) | (153.01M) | (151.52M) | [{"date":"2019-12-31","value":-1915900000,"profit":false},{"date":"2020-12-31","value":-2702400000,"profit":false},{"date":"2021-12-31","value":-5511000000,"profit":false},{"date":"2022-12-31","value":-15300700000,"profit":false},{"date":"2023-12-31","value":-15152200000,"profit":false}] |
Total Non-Operating Income/Expense | - | 86.00K | 4.00K | 11.54M | 43.27M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.2,"profit":true},{"date":"2021-12-31","value":0.01,"profit":true},{"date":"2022-12-31","value":26.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (79.25M) | (26.98M) | (55.11M) | (147.24M) | (129.45M) | [{"date":"2019-12-31","value":-7925400000,"profit":false},{"date":"2020-12-31","value":-2698100000,"profit":false},{"date":"2021-12-31","value":-5510800000,"profit":false},{"date":"2022-12-31","value":-14723900000,"profit":false},{"date":"2023-12-31","value":-12945100000,"profit":false}] |
Income Taxes | 361.00K | (232.00K) | 38.00K | 896.00K | 6.00M | [{"date":"2019-12-31","value":6.02,"profit":true},{"date":"2020-12-31","value":-3.87,"profit":false},{"date":"2021-12-31","value":0.63,"profit":true},{"date":"2022-12-31","value":14.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | (26.75M) | (55.15M) | (148.13M) | (135.45M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2674900000,"profit":false},{"date":"2021-12-31","value":-5514600000,"profit":false},{"date":"2022-12-31","value":-14813500000,"profit":false},{"date":"2023-12-31","value":-13544700000,"profit":false}] |
Income From Continuous Operations | - | (26.75M) | (55.15M) | (148.13M) | (138.30M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2674900000,"profit":false},{"date":"2021-12-31","value":-5514600000,"profit":false},{"date":"2022-12-31","value":-14813500000,"profit":false},{"date":"2023-12-31","value":-13829600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (79.61M) | (26.75M) | (55.15M) | (148.13M) | (35.47M) | [{"date":"2019-12-31","value":-7961500000,"profit":false},{"date":"2020-12-31","value":-2674900000,"profit":false},{"date":"2021-12-31","value":-5514600000,"profit":false},{"date":"2022-12-31","value":-14813500000,"profit":false},{"date":"2023-12-31","value":-3546800000,"profit":false}] |
EPS (Diluted) | - | - | (0.08) | (0.42) | (0.57) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-8,"profit":false},{"date":"2022-12-31","value":-41.58,"profit":false},{"date":"2023-12-31","value":-57,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PROK | |
---|---|
Cash Ratio | 16.16 |
Current Ratio | 17.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PROK | |
---|---|
ROA (LTM) | -20.37% |
ROE (LTM) | -31.34% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PROK | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.06 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PROK | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 91.32 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 2.13 |
ProKidney Corp. (PROK) share price today is $1.51
Yes, Indians can buy shares of ProKidney Corp. (PROK) on Vested. To buy ProKidney Corp. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PROK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of ProKidney Corp. (PROK) via the Vested app. You can start investing in ProKidney Corp. (PROK) with a minimum investment of $1.
You can invest in shares of ProKidney Corp. (PROK) via Vested in three simple steps:
The 52-week high price of ProKidney Corp. (PROK) is $4.44. The 52-week low price of ProKidney Corp. (PROK) is $1.18.
The price-to-earnings (P/E) ratio of ProKidney Corp. (PROK) is
The price-to-book (P/B) ratio of ProKidney Corp. (PROK) is 91.32
The dividend yield of ProKidney Corp. (PROK) is 0.00%
The market capitalization of ProKidney Corp. (PROK) is $1.81B
The stock symbol (or ticker) of ProKidney Corp. is PROK